Simlukafusp Alfa Regimens Show Manageable Safety and Activity But Do Not Outperform SOC in Metastatic RCC
Simlukafusp alfa plus atezolizumab with/without bevacizumab was safe and active but did not improve upon responses with SOC treatments in metastatic RCC.
Simlukafusp Alfa Plus Atezolizumab With/Without BevacizumabThe novel immunocytokine simlukafusp alfa plus atezolizumab, with or without bevacizumab, demonstrated a manageable safety profile and antitumor activity in patients with unresectable, mRCC.However, the doublet and triplet regimens did not improve response rates compared with standard therapies.Pharmacodynamic results confirmed the ability of IL-2–based therapies to induce an inflammatory infiltrate, supporting continued research of IL-2–based therapies and other novel immunocytokines in mRCC.
comments(0)
5-min edit window · permanent after that